Search This Blog

Monday, December 2, 2019

Canaccord Initiates Coverage on Galmed at Buy

Canaccord Genuity started coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a report released on Monday. The firm set a “buy” rating on the biopharmaceutical company’s stock.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)